



# Essentials of Systemic Cancer Therapies for the Oncology Nurse

## Presented by

Joaquin Buitrago, PhD  
Stella Dike, MS  
Lisa Green, MSN  
Erica Hall, MSN  
Meghan Jones, MSN

Katherine Mishaw, MS  
Tiffany Tolden, MSN  
Mildred Toth, MS  
Bindu Varghese, MN

**Tuesday, September 7<sup>th</sup> and September 14<sup>th</sup>, 2021**  
**7:45 AM-4:30 PM**

### Target Audience:

Specialties: General Oncology  
Professions: Nurse/APN

### Description:

Enable oncology nurses to apply informational resources and guidelines for knowledgeable and safe administration of systemic cancer therapies and apply evidence based nursing care interventions (including patient education), to prevent, minimize, and/or manage associated adverse effects.

Day 1 will be virtual (Zoom) and Day 2 will be on-site R11.1400 (Hickey Auditorium)

### Requirements for Successful Completion of Program:

- Register
- Attend entire learning activity
- Successfully pass post test with minimal score of 80%
- Complete evaluation within 7 days

### Nursing Objectives:

1. State principles guiding systemic cancer therapies (standard regimens and clinical trials) and response, based upon a basic understanding of carcinogenesis.
2. Address the continuum of care during the cancer journey for various patient populations
3. Discuss phases of clinical trials and the nurse's role.
4. Discuss how systemic treatments for cancer work (chemotherapy, hormone therapy, molecular targeted therapy and immunotherapy), including principles guiding cancer therapy and effects on cell proliferation.
5. Describe classifications and associated side effects of chemotherapy, hormone therapy, molecular targeted therapy and immunotherapy.
6. Articulate nursing standards and available resources that address nursing practice for safe administration of systemic cancer therapies, including patient education.
7. Discuss the process of safe administration of antineoplastic agents, including accurate calculation of body surface area (BSA) and dosing
8. Describe safety implications for the various administration routes of systemic cancer therapies.
9. Describe safe handling practices when managing hazardous drugs, including patient management, personal protective equipment (PPE) and spill management.
10. Identify prevention, recognition and management measures of local site reactions associated with vesicant extravasation, irritation and flare reactions.
11. Identify prevention, recognition and management of systemic reactions associated with drug administration including hypersensitivity, anaphylaxis and cytokine-release syndrome.
12. Identify critical assessment parameters and nursing interventions for myelosuppression caused by systemic cancer therapies.

13. Describe incidence, risk factors, assessment and interventions for management of systemic cancer therapy induced nausea and vomiting.
14. Discuss potential sexual and reproductive concerns for patients who receive cancer treatments, including assessment, communication and management strategies.
15. Discuss ethical and legal issues that nurses may face when administering systemic cancer therapies, incorporating standards, laws, and position statements as guides.
16. Apply principles, resources and standards to describe steps in pre-treatment preparation and verification, including review of treatment plans, orders, dose calculations and patient education in discussion exemplars.
17. Apply principles, resources, standards and evidence-based nursing care interventions to prevent, minimize or manage side effects and toxicities of combination systemic cancer therapies across the cancer care continuum.

**Accreditation:**

The University of Texas MD Anderson Cancer Center is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

**Credit Designation:**

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 15.04 Nursing contact hour(s) which includes APRN 5.4 Pharmacotherapeutics credit(s).

**Commercial Support:**

No commercial support has been received for this activity.

**Faculty & Planner Disclosure:**

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
Dee Marks, MBA	Activity Administrator	Nothing to disclose
Stella Dike, MSN	Nurse Planner, Faculty	Nothing to disclose
Mildred Toth, MS	Nurse Planner, Faculty	Nothing to disclose
Erica Hall, MSN	Other Planning Committee Member, Faculty	Nothing to disclose
Joaquin Buitrago, PhD	Faculty	Nothing to disclose - 02/01/2021
Lisa Green, MSN	Faculty	Nothing to disclose - 12/18/2020
Meghan Jones, MSN	Faculty	Nothing to disclose - 02/01/2021
Katherine Mishaw, MS	Faculty	Nothing to disclose - 01/29/2021
Tiffany Tolden, MSN	Faculty	Nothing to disclose - 01/29/2021
Bindu Varghese, MN	Faculty	Nothing to disclose - 01/29/2021